Iloperidone (Fanapt) vs Paliperidone palmitate (Invega Trinza)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Iloperidone (Fanapt)
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Reported efficacy
Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)
Result source: NCT00254202
Paliperidone palmitate (Invega Trinza)
Marketed by Johnson & Johnson
NCT02713282 · Phase 3 · completed
This was a single-group, open-label study without randomization or a comparator arm, so it could not directly compare the 3-month formulation with placebo or another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)
Result source: NCT04072575
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Iloperidone (Fanapt) | Paliperidone palmitate (Invega Trinza) |
|---|---|---|
| PANSS total, change | -12 vs -7.1−4.9 vs placeboNCT002542021 other result
| -1.8 vs -1.6vs PP3MNCT03345342 |
| CGI-S, change | —Trial running · NCT06961968 | 0 vs 0vs PP3MNCT033453422 other results
|
| PANSS response | —Trial running · NCT06961968 | —Not posted · NCT02713282 |
| PSP, change | —Trial running · NCT06961968 | 1 vs 1.1vs PP3MNCT033453422 other results
|
| Relapse (% of patients) | —Trial running · NCT06961968 | —Not posted · NCT02713282 |
PANSS total, change
- Iloperidone (Fanapt)
- -12 vs -7.1−4.9 vs placeboNCT00254202
1 other result
- 1.1 vs 12.4 NCT01291511
- Paliperidone palmitate (Invega Trinza)
- -1.8 vs -1.6vs PP3MNCT03345342
CGI-S, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Paliperidone palmitate (Invega Trinza)
- 0 vs 0vs PP3MNCT03345342
2 other results
- -0.2 vs -0.3 NCT02431702
- -0.7 vs -0.7 NCT02431702
PANSS response
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Paliperidone palmitate (Invega Trinza)
- —Not posted · NCT02713282
PSP, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Paliperidone palmitate (Invega Trinza)
- 1 vs 1.1vs PP3MNCT03345342
2 other results
- 7.5 vs 7 NCT02431702
- 2.5 vs 2.9 NCT02431702
Relapse (% of patients)
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Paliperidone palmitate (Invega Trinza)
- —Not posted · NCT02713282
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Iloperidone (Fanapt): 5 of 5 rows · Paliperidone palmitate (Invega Trinza): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Iloperidone (Fanapt) | Paliperidone palmitate (Invega Trinza) |
|---|---|---|
| Time to Relapse time to event · months | NA vs 3.25 placebo months @ 26wka,b,c NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 | NA vs NA PP3M months @ 52wka,b,c NCT03345342 · Phase 3 · Schizophrenia · phase 3 |
| Dropout rate | 34.6%d NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results51.3%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 30.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 31.5%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence 18.8%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 12.5%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 13.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | —Double-blind PP6Me NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more results—Follow-up Phase PP6M NCT03345342 · Phase 3 · Schizophrenia · phase 3 13.5%700 or 1000 mg eq NCT04072575 · Phase 3 · combination — NCT01529515 · Phase 3 —Part 2-Paliperidone Palmitate (PP) NCT02431702 · Phase 3 · registry result, not featured evidence · combination —Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 · registry result, not featured evidence —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —d NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results14.5%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 10.4%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 15%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | —Double-blind PP6Me NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more results—Follow-up Phase PP6M NCT03345342 · Phase 3 · Schizophrenia · phase 3 3.9%700 or 1000 mg eq NCT04072575 · Phase 3 · combination — NCT01529515 · Phase 3 —Part 2-Paliperidone Palmitate (PP) NCT02431702 · Phase 3 · registry result, not featured evidence · combination —Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 · registry result, not featured evidence —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0.7%d NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results—Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 4%Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 2.7%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 14.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 7.1%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 5%Double-blind PP6Me NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more results5.5%Follow-up Phase PP6M NCT03345342 · Phase 3 · Schizophrenia · phase 3 4.5%700 or 1000 mg eq NCT04072575 · Phase 3 · combination 2.5% NCT01529515 · Phase 3 12.8%Part 2-Paliperidone Palmitate (PP) NCT02431702 · Phase 3 · registry result, not featured evidence · combination 5.3%Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 · registry result, not featured evidence 2%Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | d headache 20.3% (placebo 19.7%) dizziness 17% (placebo 7.5%) sedation 12.7% (placebo 8.2%) NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 18 more resultsdizziness 11.6% (placebo 2.7%) somnolence 8.3% (placebo 0%) dry mouth 6.8% (placebo 0%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dizziness 2.6% (placebo 2.7%) headache 2% (placebo 3.3%) insomnia 2% (placebo 4.7%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dry mouth 17.9% dizziness 17.5% somnolence 14.2% NCT01207414 · Phase 4 · registry result, not featured evidence dizziness 22.3% dry mouth 20.8% insomnia 9.6% NCT01207414 · Phase 4 · registry result, not featured evidence 625 mg injection site pain 66.7% injection site induration 60% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 625 mg headache 20% nasal congestion 20% anxiety 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg injection site pain 60% injection site induration 26.7% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg nasal congestion 33.3% constipation 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg back pain 7.1% constipation 7.1% headache 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg insomnia 20% headache 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg constipation 14.3% headache 14.3% anxiety 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg headache 33.3% insomnia 33.3% dyspepsia 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg injection site pain 53.3% headache 26.7% nasal congestion 26.7% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg nasal congestion 40% headache 26.7% oropharyngeal pain 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg pruritus 50% throat irritation 50% upper respiratory tract infection 50% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg constipation 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg blood creatine phosphokinase increased 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg dizziness 50% headache 50% agitation 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence | e weight increased 8.4% injection site pain 7.7% headache 6.7% NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more resultsnasopharyngitis 3.7% upper respiratory tract infection 0.9% headache 0% NCT03345342 · Phase 3 · Schizophrenia · phase 3 700 or 1000 mg eq headache 13.5% blood prolactin increased 10.7% hyperprolactinaemia 7.3% NCT04072575 · Phase 3 · combination headache 8.8% (placebo 4.1%) weight increased 8.8% (placebo 3.4%) anxiety 8.1% (placebo 10.3%) NCT01529515 · Phase 3 weight increased 28.2% akathisia 9% headache 9% NCT02431702 · Phase 3 · registry result, not featured evidence · combination weight increased 15.8% anxiety 10.5% insomnia 10.5% NCT02431702 · Phase 3 · registry result, not featured evidence weight increased 14.3% insomnia 10.2% nasopharyngitis 6.1% NCT02431702 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation context differs: baseline_threshold differs (panss<=100 versus bmi>=17, panss<70); prior_therapy differs (experienced versus none recorded).
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 26 weeks versus 52 weeks.
- dPopulation comparability has not been reviewed for 21 of these studies.
- ePopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Iloperidone (Fanapt)
show 1 more result
show 3 more results
Paliperidone palmitate (Invega Trinza)
show 2 more results
show 2 more results
show 1 more result
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Paliperidone palmitate (Invega Trinza)'s landscape